ICU Medical Inc (NASDAQ: ICUI) reported Q2 sales of $561 million, up 75% Y/Y, due to Smiths Medical's acquisition, and missing the consensus of $566.47 million. Adjusted EPS fell from $1.88 to $1.37, missing the consensus of $1.86. Guidance: ICU Medical forecasts FY22 adjusted EBITDA of $350-$370 million, down from a prior range of $450-$500 million, and adjusted EPS of $6.20 - $6.80, compared to $9.00 - $10.50 expected earlier. Raymond James writes that while legacy ICUI continues to perform we
ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Company Updated FY 2022 GuidanceSAN CLEMENTE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2022. Second Quarter 2022 Results Second quarter 2022 revenue was $561.0 million, compared to $321.7 million in the same period last year. GAAP gross profit for the second quarter of 2022 was $167.6 million, as compared to $123.5 mi